Home Cart Sign in  
Chemical Structure| 144675-97-8 Chemical Structure| 144675-97-8

Structure of Pixantrone
CAS No.: 144675-97-8

Chemical Structure| 144675-97-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pixantrone dimaleate is a topoisomerase II inhibitor and DNA intercalator, with anti-tumor activity. Pixantrone dimaleate is an experimental antineoplastic drug.

Synonyms: Pixantrone (maleate); Pixantrone Maleate; BBR 2778

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pixantrone

CAS No. :144675-97-8
Formula : C25H27N5O10
M.W : 557.51
SMILES Code : O=C(C1=C(NCCN)C=CC(NCCN)=C12)C3=C(C=NC=C3)C2=O.O=C(O)/C=C\C(O)=O.O=C(O)/C=C\C(O)=O
Synonyms :
Pixantrone (maleate); Pixantrone Maleate; BBR 2778
MDL No. :MFCD00920108

Safety of Pixantrone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H341-H361
Precautionary Statements:P201-P202-P280-P308+P313-P405-P501

Related Pathways of Pixantrone

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Escherichia coli ATCC 25922 32 µg/mL 16-24 hours Evaluate the synergistic antimicrobial activity between Pixantrone and rifampin, results showed Pixantrone significantly enhanced the antimicrobial effect of rifampin PMC9769682
Pseudomonas aeruginosa PAO1 32 µg/mL 16-24 hours Evaluate the synergistic antimicrobial activity between Pixantrone and rifampin, results showed Pixantrone significantly enhanced the antimicrobial effect of rifampin PMC9769682
Klebsiella pneumoniae ATCC 700603 32 µg/mL 16-24 hours Evaluate the synergistic antimicrobial activity between Pixantrone and rifampin, results showed Pixantrone significantly enhanced the antimicrobial effect of rifampin PMC9769682
Acinetobacter baumannii ATCC 19606 32 µg/mL 16-24 hours Evaluate the synergistic antimicrobial activity between Pixantrone and rifampin, results showed Pixantrone significantly enhanced the antimicrobial effect of rifampin PMC9769682
Huh-7 cells 5 µM 36 hours Screening for compounds inhibiting LASV genome replication, Pixantrone maleate inhibited LASV MG activity by over 90% PMC9866940
A549 cells 5 µM 48 hours Evaluating the inhibitory effect of Pixantrone maleate on JUNV replication, IC50 value of 3.66 µM PMC9866940

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nu/nu mice A549 tumor model Tail vein injection 10 mg Pix/kg Injected on days 14, 17, 20, 23, and 26, continued until day 32 To evaluate the anti-tumor effect of Pix-PSL in the A549 tumor model, results showed that the Pix-PSL group had significantly better tumor growth inhibition compared to other Pix formulation groups. PMC6060708
ICR mice Peritonitis-sepsis model and subcutaneous abscess model Intraperitoneal injection 30 mg/kg Single dose, observed for 7 days Evaluate the in vivo antimicrobial efficacy of combination therapy, results showed the combination significantly improved survival rates and reduced abscess area and bacterial load PMC9769682

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01321541 Diffuse Large B-cell Lymphoma ... More >> de Novo DLBCL DLBCL Transformed From Indolent Lymphoma Follicular Grade 3 Lymphoma Less << Phase 3 Completed - -
NCT00069966 Lymphoma Phase 2 Unknown - -
NCT00551239 Leukemia Lymp... More >>homa Less << Phase 3 Unknown - United States, Washington ... More >> Cell Therapeutics, Incorporated Seattle, Washington, United States, 98119 Less <<
NCT01086605 Breast Cancer Phase 2 Completed - -
NCT01086605 - Completed - -
NCT00053105 Lymphoma Phase 1 Unknown - United States, Arizona ... More >> Arizona Clinical Research Center Tucson, Arizona, United States, 85712 United States, Arkansas Highlands Oncology Group Springdale, Arkansas, United States, 72764 United States, California USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90033-0800 United States, Maryland Marlene and Stewart Greenebaum Cancer Center, University of Maryland Baltimore, Maryland, United States, 21201 United States, Ohio Ireland Cancer Center Cleveland, Ohio, United States, 44106-5055 United States, Tennessee Boston Baskin Cancer Group, University Tennessee Memphis, Tennessee, United States, 38104 United States, Texas University of Texas - MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02800889 Lymphoma|Solid Tumor (Excludin... More >>g CNS) Less << PHASE1 WITHDRAWN 2018-07-10 Children's Hospital Los Angele... More >>s, Los Angeles, California, 90027, United States Less <<
NCT01632436 Metastatic Cancer PHASE1 WITHDRAWN 2025-02-18 UTHSCSA-Cancer Therapy-Researc... More >>h Center, San Antonio, Texas, 78229, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.79mL

0.36mL

0.18mL

8.97mL

1.79mL

0.90mL

17.94mL

3.59mL

1.79mL

References

 

Historical Records

Categories